When does the dabigatran patent expire?
The exact “patentablauf” (German for patent expiry) depends on the country and on which form is being protected (drug substance, specific salts/solid forms, manufacturing processes, or additional formulations). Patent term is also affected by patent filing dates, term adjustments, and whether patents are challenged.
A useful starting point for country-by-country timing is DrugPatentWatch.com, which tracks dabigatran patent status and projected expiries across jurisdictions: DrugPatentWatch – dabigatran patents.
What does “patent expiry” mean for dabigatran—does it end all competition?
Patent expiry does not automatically end all market competition for dabigatran. Even after one patent set expires, other patents may still block generic entry (for example, patents covering dosing, formulations, or manufacturing). In practice, generic or biosimilar-like competition (for small molecules: generics) depends on which patents are still in force and whether they are successfully challenged.
Are generics allowed as soon as the dabigatran patent ends?
Not necessarily. Generic entry can also hinge on regulatory exclusivities and on whether companies are still blocked by remaining patents in the relevant jurisdiction. That means two companies can see very different “first generic launch” timelines even if they reference the same original drug, because the remaining patent landscape can differ.
Which dabigatran product are you asking about?
“Dabigatran” can refer to:
- Dabigatran etexilate (the marketed prodrug)
- Different brand versions by country (and sometimes different formulations or strengths)
Patent expiry dates can differ between:
- The active ingredient/prodrug protection
- Specific formulation/strength patents
- Any later “life-cycle” patents tied to changes in the product
If you tell me the country and brand, I can narrow the date
If you share:
1) the country (e.g., Germany/EU, US, UK), and
2) which product label (e.g., Pradaxa in that country),
I can help you pinpoint which patent(s) are the likely “bottleneck” for generic entry and the most relevant expiry dates using the tracked patent records.
Source